# A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

> **NCT04036461** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 47 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-99712
- **DRUG:** BMS-986405

## Key facts

- **NCT ID:** NCT04036461
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-26
- **Primary completion:** 2024-07-08
- **Final completion:** 2024-08-19
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2024-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04036461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04036461, "A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04036461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*